Hexagon Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $810K | Sell |
17,509
-332
| -2% | -$15.4K | 0.18% | 47 |
|
|
2025
Q1 | $1.09M | Buy |
17,841
+567
| +3% | +$34.6K | 0.21% | 53 |
|
|
2024
Q4 | $977K | Buy |
17,274
+1,465
| +9% | +$82.9K | 0.18% | 58 |
|
|
2024
Q3 | $818K | Buy |
15,809
+4,080
| +35% | +$211K | 0.16% | 63 |
|
|
2024
Q2 | $487K | Sell |
11,729
-3,948
| -25% | -$164K | 0.11% | 98 |
|
|
2024
Q1 | $850K | Buy |
15,677
+1,636
| +12% | +$88.7K | 0.19% | 55 |
|
|
2023
Q4 | $720K | Buy |
14,041
+3,955
| +39% | +$203K | 0.17% | 63 |
|
|
2023
Q3 | $585K | Buy |
10,086
+887
| +10% | +$51.5K | 0.15% | 69 |
|
|
2023
Q2 | $588K | Buy |
9,199
+491
| +6% | +$31.4K | 0.16% | 63 |
|
|
2023
Q1 | $604K | Buy |
8,708
+102
| +1% | +$7.07K | 0.17% | 60 |
|
|
2022
Q4 | $619K | Sell |
8,606
-1,078
| -11% | -$77.6K | 0.18% | 56 |
|
|
2022
Q3 | $688K | Buy |
9,684
+1,976
| +26% | +$140K | 0.2% | 55 |
|
|
2022
Q2 | $593K | Sell |
7,708
-462
| -6% | -$35.5K | 0.18% | 70 |
|
|
2022
Q1 | $597K | Sell |
8,170
-577
| -7% | -$42.2K | 0.16% | 74 |
|
|
2021
Q4 | $545K | Buy |
8,747
+1,991
| +29% | +$124K | 0.14% | 84 |
|
|
2021
Q3 | $400K | Buy |
6,756
+265
| +4% | +$15.7K | 0.12% | 94 |
|
|
2021
Q2 | $434K | Buy |
6,491
+641
| +11% | +$42.9K | 0.12% | 89 |
|
|
2021
Q1 | $369K | Buy |
5,850
+294
| +5% | +$18.5K | 0.1% | 87 |
|
|
2020
Q4 | $344K | Buy |
5,556
+410
| +8% | +$25.4K | 0.1% | 84 |
|
|
2020
Q3 | $306K | Buy |
+5,146
| New | +$306K | 0.1% | 90 |
|